Hao Chen Selected Research

Tubulin Modulators

1/2022	Colchicine-Binding Site Agent CH-2-77 as a Potent Tubulin Inhibitor Suppressing Triple-Negative Breast Cancer.
10/2021	Nanoformulation design and therapeutic potential of a novel tubulin inhibitor in pancreatic cancer.
12/2020	Orally available tubulin inhibitor VERU-111 enhances antitumor efficacy in paclitaxel-resistant lung cancer.
1/2020	An Orally Available Tubulin Inhibitor, VERU-111, Suppresses Triple-Negative Breast Cancer Tumor Growth and Metastasis and Bypasses Taxane Resistance.
1/2019	Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy.
8/2018	Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3 targeting the colchicine binding site.
8/2017	Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hao Chen Research Topics

Disease

433	Neoplasms (Cancer) 11/2022 - 10/2004
96	Inflammation (Inflammations) 10/2022 - 03/2006
90	Infections 06/2022 - 01/2004
89	Neoplasm Metastasis (Metastasis) 10/2022 - 09/2009
78	Stomach Neoplasms (Stomach Cancer) 04/2022 - 02/2004
60	Pancreatic Neoplasms (Pancreatic Cancer) 10/2022 - 03/2008
51	Hepatocellular Carcinoma (Hepatoma) 04/2022 - 09/2010
44	Adenocarcinoma 05/2022 - 09/2011
43	Breast Neoplasms (Breast Cancer) 06/2022 - 02/2012
42	Carcinogenesis 06/2022 - 11/2004
29	Hypoxia (Hypoxemia) 07/2022 - 01/2015
27	Colorectal Neoplasms (Colorectal Cancer) 10/2022 - 08/2013
23	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2022 - 10/2012
23	COVID-19 03/2022 - 01/2020
23	Pain (Aches) 01/2022 - 11/2008
22	Wounds and Injuries (Trauma) 01/2022 - 06/2008
21	Reperfusion Injury 01/2022 - 06/2004
21	Fibrosis (Cirrhosis) 01/2022 - 05/2004
17	Ischemia 01/2022 - 01/2007
16	Atherosclerosis 06/2022 - 06/2005
16	Carcinoma (Carcinomatosis) 01/2022 - 04/2017
16	Nasopharyngeal Carcinoma 12/2021 - 01/2013
16	Lymphatic Metastasis 12/2021 - 06/2005
15	Sepsis (Septicemia) 10/2022 - 02/2006
15	Lung Neoplasms (Lung Cancer) 01/2022 - 02/2013
15	Body Weight (Weight, Body) 09/2021 - 08/2003
15	Melanoma (Melanoma, Malignant) 03/2021 - 03/2011
14	Necrosis 10/2021 - 10/2013
14	Hemorrhage 09/2021 - 03/2008
13	Hypersensitivity (Allergy) 10/2022 - 06/2007
13	Bacterial Infections (Bacterial Infection) 09/2022 - 12/2016
13	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2022 - 10/2008
13	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 01/2022 - 01/2012
13	Esophageal Squamous Cell Carcinoma 10/2021 - 12/2012
13	Glioma (Gliomas) 01/2021 - 12/2013
12	Myopia 07/2022 - 04/2016
12	Cataract (Cataracts) 07/2022 - 10/2014
12	Myocardial Infarction 02/2022 - 06/2015
11	Rheumatoid Arthritis 01/2022 - 01/2014
11	Prostatic Neoplasms (Prostate Cancer) 03/2019 - 09/2016
10	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 10/2004
10	Liver Neoplasms (Liver Cancer) 01/2022 - 01/2014
10	Osteoporosis 12/2021 - 05/2017

Drug/Important Bio-Agent (IBA)

136	Proteins (Proteins, Gene)FDA Link 06/2022 - 04/2002
91	Biomarkers (Surrogate Marker)IBA 05/2022 - 01/2013
87	Pharmaceutical PreparationsIBA 10/2022 - 06/2004
52	MicroRNAs (MicroRNA)IBA 07/2022 - 01/2012
49	CytokinesIBA 08/2022 - 05/2004
40	Biological ProductsIBA 04/2022 - 05/2012
37	Long Noncoding RNAIBA 06/2022 - 12/2013
37	Messenger RNA (mRNA)IBA 02/2022 - 01/2007
34	DNA (Deoxyribonucleic Acid)IBA 03/2022 - 10/2004
26	RNA (Ribonucleic Acid)IBA 03/2022 - 12/2008
21	EnzymesIBA 01/2022 - 06/2005
21	Glucose (Dextrose)FDA LinkGeneric 11/2021 - 08/2010
20	HydrogelsIBA 07/2022 - 06/2012
18	Indicators and Reagents (Reagents)IBA 10/2022 - 11/2007
18	CateninsIBA 10/2022 - 01/2014
18	Transcription Factors (Transcription Factor)IBA 06/2022 - 09/2011
18	Therapeutic UsesIBA 01/2022 - 03/2007
18	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 02/2006
17	LipidsIBA 07/2022 - 01/2014
16	AntigensIBA 04/2022 - 05/2004
16	Small Interfering RNA (siRNA)IBA 01/2022 - 09/2011
16	Cisplatin (Platino)FDA LinkGeneric 12/2021 - 12/2012
15	Retinaldehyde (Retinal)IBA 02/2022 - 04/2002
15	Interleukin-6 (Interleukin 6)IBA 01/2022 - 02/2012
15	Peptides (Polypeptides)IBA 01/2022 - 09/2007
14	InflammasomesIBA 01/2022 - 01/2017
14	Immunoglobulin G (IgG)IBA 01/2022 - 06/2005
14	salicylhydroxamic acid (SHAM)IBA 01/2022 - 01/2007
13	Immune Checkpoint InhibitorsIBA 12/2022 - 01/2019
13	Interleukin-10 (Interleukin 10)IBA 01/2022 - 11/2006
13	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022 - 06/2005
13	AntibodiesIBA 01/2022 - 01/2013
13	Doxorubicin (Adriamycin)FDA LinkGeneric 09/2021 - 03/2006
13	VaccinesIBA 01/2021 - 11/2007
12	AntioxidantsIBA 02/2022 - 12/2007
11	Phosphotransferases (Kinase)IBA 01/2022 - 01/2012
11	Inosine Triphosphate (ITP)IBA 01/2022 - 01/2012
11	LigandsIBA 01/2022 - 11/2013
11	CholesterolIBA 01/2022 - 01/2015
11	Gemcitabine FDA Link 12/2021 - 06/2013
10	NucleotidesIBA 11/2022 - 08/2017
10	LipopolysaccharidesIBA 08/2022 - 03/2008
10	ChemokinesIBA 05/2022 - 06/2012
10	Adenosine Triphosphate (ATP)IBA 04/2022 - 03/2012

Therapy/Procedure

164	Therapeutics 09/2022 - 03/2008
74	Drug Therapy (Chemotherapy) 06/2022 - 05/2002
32	Immunotherapy 12/2022 - 10/2015
20	Length of Stay 01/2022 - 11/2014
19	Radiotherapy 02/2022 - 02/2012
18	Gastrectomy 02/2022 - 02/2014
15	Chinese Traditional Medicine (Traditional Chinese Medicine) 01/2022 - 11/2013
14	Transplantation 05/2022 - 06/2004
13	Liver Transplantation 01/2022 - 06/2004
12	Adjuvant Chemotherapy 12/2021 - 01/2017
11	Injections 07/2022 - 09/2011
11	Precision Medicine 07/2022 - 01/2017
10	Intraocular Lenses (Intraocular Lens) 05/2022 - 10/2014